12 research outputs found
Parietal Bone Metastasis of Rectal Adenocarcinoma as an Initial Diagnosis of Recurrence: Case Report CASE REPORT Open Access
Colorectal cancer (CRC) is a most common and lethal disease of the gastrointestinal tract [1]. CRC can usually spread by lymphatic and hematogenous routes. The most common metastatic sites are the regional lymph nodes, liver, lungs, and peritoneum [1]. Uncommon metastasis of CRC were described such as skin, muscles, skull and thyroid [2][3] A 44-year old man had diagnosed with adenocarcinoma of the rectum as a result of colonoscopic biopsy in July 2009. Fluoropyrimidine-based neoadjuvant chemoradiotherapy had performed. "Low Anterior Resection" was held in September 2009 and after surgery 4 cycles adjuvant chemotherapy had admitted. The patient was followed in remission until February 2012. He had presented with a mass approximately 6 cm in diameter located his temporoparietal region in February 2012. The mass had grown rapidly in 4 or 5 months. Because of tumour diameter and pain, he had applied to Neurosurgery Department. Magnetic resonance imaging (MRI) showed a 6.0x4.0 cm mass, extending from bottom of scalp and epidural space Parietal Bone Metastasis of Rectal Adenocarcinoma as an Initial Abstract Keywords: Skull metastasis; Parietal bone metastasis; Metastatic colorectal cance
Multiple primary cancers associated with endometrial and ovarian cancers: An analysis based upon the Japan Autopsy Annual Database from 2002 to 2010
Novel methodology on direct extraction of the strength information from cementitious materials using piezo-sensor based electromechanical impedance (EMI) method
Squamous cell carcinoma of the lung and pulmonary metastasis of papillary thyroid carcinoma: a case report
Clinical Analysis of 152 Cases of Multiple Primary Malignant Tumors in 15,398 Patients with Malignant Tumors
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma.
BACKGROUND: We examined the impact of adjuvant modalities on resected pancreatic and periampullary adenocarcinoma (PAC). METHODS: A total of 563 patients who were curatively resected for PAC were retrospectively analyzed between 2003 and 2013. RESULTS: Of 563 patients, 472 received adjuvant chemotherapy (CT) alone, chemoradiotherapy (CRT) alone, and chemoradiotherapy plus chemotherapy (CRT-CT) were analyzed. Of the 472 patients, 231 were given CRT-CT, 26 were given CRT, and 215 were given CT. The median recurrence-free survival (RFS) and overall survival (OS) were 12 and 19 months, respectively. When CT and CRT-CT groups were compared, there was no significant difference with respect to both RFS and OS, and also there was no difference in RFS and OS among CRT-CT, CT and CRT groups. To further investigate the impact of radiation on subgroups, patients were stratified according to lymph node status and resection margins. In node-positive patients, both RFS and OS were significantly longer in CRT-CT than CT. In contrast, there was no significant difference between groups when patients with node-negative disease or patients with or without positive surgical margins were considered. CONCLUSIONS: Addition of radiation to CT has a survival benefit in patients with node-positive disease following pancreatic resection